Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition

Group 1: Company Overview - Lantern Pharma, Inc. (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company focused on oncology drug discovery and development using artificial intelligence, machine learning, and genomics [7] - The company has established an Artificial Intelligence Center of Excellence and Advanced Agentic Labs in Bengaluru, India, aimed at scaling its proprietary RADR AI platform for global biopharma use [4] Group 2: Recent Developments - On January 20, the FDA granted Lantern Pharma's LP-284 an Orphan Drug Designation (ODD), which supports the development of treatments for diseases affecting fewer than 200,000 people [1][3] - This ODD designation for LP-284 is the third for this molecule, with previous designations for mantle cell lymphoma in January 2023 and high-grade B-cell lymphoma in November 2023 [3] Group 3: RADR AI Platform - The RADR platform integrates hundreds of billions of oncology-focused data points, sophisticated machine learning algorithms, and curated disease models to identify biomarkers, predict drug responses, and optimize clinical strategies [6] - The Bengaluru facility will serve as a global scale-up hub for RADR, expanding computational capacity and developing machine learning-ready disease models [5]